Play-by-play of Gilead’s $21B Immunomedics buyout details a frenzied push leading up to ESMO

Immunomedics had not really been looking for a buyout when the year began. Excited by its BLA for Trodelvy, submitted to the FDA in late 2019, executive chairman Behzad Aghazadeh started off looking for potential licensing deals and zeroed in on four potential partners, including Gilead, following January’s JP Morgan…

Click to view original post